# US 11,433,043 B2 · Compounds useful for increasing neurogenesis in neural tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,043 B2
- Document ID: US11433043B2
- Status: Granted
- Kind: B2
- Application number: 16/906,814
- Filed: 2020-06-19
- Published: 2020-10-15
- Granted: 2022-09-06
- Earliest claimed: 2010-06-16
- Assignees: Alfasigma S.P.A.
- Applicants: Alfasigma S.P.A.
- Inventors: Mariagrazia Grilli; Pier Luigi Canonico; Aleardo Koverech
- Web page: https://patentgrep.com/patent/US11433043B2

## CPC

- A61K 31/225: Polycarboxylic acids
- A61K 31/205: Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention described herein is directed to the use of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in which said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.

## Claims

### Claim 1

A method for increasing neurogenesis in a patient in need thereof, said method consisting of administering to said patient in need a dose of an active agent, said active agent consisting of acetyl L-carnitine or a salt thereof, wherein said dose corresponds to 1.00 g/day to 2.00 g/day administered in a single or multiple doses, and
increasing said neurogenesis in said patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the salt of acetyl L-carnitine is selected from the group consisting of: chloride, bromide, orotate, aspartate, acid aspartate, acid citrate, magnesium citrate, phosphate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, oxalate, acid oxalate, pamoate, acid pamoate, sulphate, acid sulphate, glucose phosphate, tartrate and acid tartrate, glycerophosphate, mucate, magnesium tartrate, 2-amino-ethanesulphonate, magnesium 2-amino-ethanesulphonate, methanesulphonate, choline tartrate, trichloroacetate, and trifluoroacetate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the acetyl L-carnitine is administered in a dose of 1.5 g/day, in a single or multiple doses.

### Claim 4 (depends on 1)

The method of claim 1, wherein the acetyl L-carnitine is administered by oral, subcutaneous, transdermal, intraperitoneal, intramuscular, in vein, intracerebroventricular, intraparenchymal, intrathecal, intracranial, buccal, mucosal, nasal, pulmonary, rectal administration or by a liposome delivery system.